Merck & Co. Inc. (MRK)

85.66
1.70 2.00
NYSE : Health Technology
Prev Close 83.97
Open 84.74
Day Low/High 84.32 / 85.79
52 Wk Low/High 66.10 / 87.35
Volume 9.47M
Avg Volume 9.66M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 212.56B
EPS 2.30
P/E Ratio 38.92
Div & Yield 2.20 (2.58%)
Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

New Research From Merck's Broad Oncology Clinical Development Program To Be Presented At 2019 ASCO Annual Meeting

New Research From Merck's Broad Oncology Clinical Development Program To Be Presented At 2019 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new research from the company's broad oncology clinical development program will be presented at the 55 th Annual Meeting of the American Society of Clinical...

Cancer Patients And Caregivers Write Letters To Themselves As Part Of The "With Love, Me" Campaign

Cancer Patients And Caregivers Write Letters To Themselves As Part Of The "With Love, Me" Campaign

Merck today announced a collaboration with journalist, author and longtime cancer advocate, Katie Couric, to launch "With Love, Me," a new feature of Merck's U.

Merck Announces Results From Phase 2 Trial Of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) In Infants

Merck Announces Results From Phase 2 Trial Of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) In Infants

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal...

Merck's BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial For The Treatment Of Insomnia In People With Mild-to-Moderate Alzheimer's Disease Dementia

Merck's BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial For The Treatment Of Insomnia In People With Mild-to-Moderate Alzheimer's Disease Dementia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA ® (suvorexant) C-IV for the treatment of insomnia in people with...

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

Stocks ended mixed as the S&P 500 set a record close and the Nasdaq slumped on a revenue miss from Alphabet.

Jim Cramer Weighs In on Merck, General Electric and McDonald's Earnings

Jim Cramer Weighs In on Merck, General Electric and McDonald's Earnings

Curious about what Jim Cramer's keeping an eye on during the middle of earnings season.

Merck Smashes Q1 Earnings Estimate, Boosts 2019 Outlook, as Keytruda Sales Surge

Merck Smashes Q1 Earnings Estimate, Boosts 2019 Outlook, as Keytruda Sales Surge

Merck posted stronger-than-expected first quarter earnings Tuesday, and lifted its 2019 profit guidance, as its blockbuster lung cancer treatment topped $2.2 billion.

Jim Cramer Tackles Elon Musk's Tweets, Alphabet, Apple and Market Movers

Jim Cramer Tackles Elon Musk's Tweets, Alphabet, Apple and Market Movers

Jim Cramer weighs in on Alphabet's earnings, his definition of "shallowfake" and he's looking ahead to Apple's earnings.

Jim Cramer Defines 'Shallowfake' for Elon Musk, Talks Alphabet and Apple - Live

Jim Cramer Defines 'Shallowfake' for Elon Musk, Talks Alphabet and Apple - Live

Jim Cramer tackles Alphabet's earnings, his definition of "shallowfake" and he's looking ahead to Apple's earnings. Watch it all live at 10 E.T.

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Global stocks slipped lower for a second consecutive session Tuesday, pulling U.S. equity futures into the red, as investors reacted to renewed weakness in China's manufacturing sector and braced for the impact of softer-than-expected revenue gains from online ad giant Alphabet Inc.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2019.

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Merck Expected to Earn $1.05 a Share

Merck Expected to Earn $1.05 a Share

Merck revenue expected to rise 4.3% to $10.5 billion.

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Global stocks were mixed Monday as investors extended bets that surging economic growth, stronger-than-expected corporate earnings and a potentially dovish Federal Reserve will continue to push U.S. stocks to fresh record highs.

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For First-Line Maintenance Treatment In BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For First-Line Maintenance Treatment In BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending LYNPARZA as...

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Merck Provides Update On Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

Merck Provides Update On Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy and in combination with...

Merck And Viola Davis To Debut A Touch Of Sugar During Tribeca Film Festival®

Merck And Viola Davis To Debut A Touch Of Sugar During Tribeca Film Festival®

Acclaimed Actress Narrates Documentary Aimed at Confronting America's Type 2 Diabetes Crisis

FDA Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma (RCC)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #8 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #90 spot out of 500.

Results Of Phase 3 Trial Evaluating Merck's ZERBAXA® (ceftolozane And Tazobactam) Versus Meropenem For Treatment Of Adult Patients With Ventilated Nosocomial Pneumonia (VNP) To Be Presented At ECCMID 2019

Results Of Phase 3 Trial Evaluating Merck's ZERBAXA® (ceftolozane And Tazobactam) Versus Meropenem For Treatment Of Adult Patients With Ventilated Nosocomial Pneumonia (VNP) To Be Presented At ECCMID 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA ®...

FDA Approves Expanded Monotherapy Label For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves Expanded Monotherapy Label For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

LYNPARZA® (olaparib) Approved In EU For The Treatment Of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Approved In EU For The Treatment Of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has approved LYNPARZA as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (g BRCAm), and who...

Merck Completes Tender Offer To Acquire Immune Design

Merck Completes Tender Offer To Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design (NASDAQ: IMDZ) at a purchase price...

Merck To Hold First-Quarter 2019 Sales And Earnings Conference Call On April 30

Merck To Hold First-Quarter 2019 Sales And Earnings Conference Call On April 30

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.

TheStreet Quant Rating: A+ (Buy)